Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365383 | 0.91 | MAPK14 (0.57) | MAPK14PTGS2PTGS1KIF11CYP2C9 | |
| SCHEMBL5365336 | 0.90 | MAPK14 (0.56) | MAPK14PTGS2PTGS1KIF11CSNK1A1 | |
| SCHEMBL5377681 | 0.89 | MAPK14 (0.69) | MAPK14PTGS2CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5366953 | 0.88 | MAPK14 (0.54) | MAPK14PTGS2PTGS1KIF11CYP2C9 | |
| SCHEMBL5372635 | 0.84 | PTGS2 (0.60) | MAPK14PTGS2PTGS1 | |
| SCHEMBL6594280 | 0.84 | PTGS1 (0.57) | MAPK14PTGS2PTGS1CSNK1A1CSNK1D | |
| SCHEMBL6594699 | 0.84 | MAPK14 (0.68) | MAPK14PTGS2PTGS1CSNK1A1CSNK1D | |
| SCHEMBL5365333 | 0.82 | MAPK14 (0.61) | MAPK14PTGS2PTGS1CSNK1A1CSNK1D | |
| SCHEMBL5388978 | 0.82 | MAPK14 (1.00) | MAPK14KIF11CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL6591441 | 0.81 | MAPK14 (0.70) | MAPK14PTGS2PTGS1CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223772-B1 | Pyrazolopyridine derivatives as selective cox-2 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-29 | — | — | US | claimed |
| CN-1263755-C | Pyrazolopyridine derivatives as selective COX-2 inhibitors | GLAXO GROUP LTD (GB) | 2006-07-12 | — | — | CN | claimed |
| EP-1127058-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LTD (GB) | 2004-09-01 | — | — | EP | claimed |
| CN-1332741-A | Pyrazolopyridine derivatives as selective COX-2 inhibitors | GLAZO GROUP LTD (GB) | 2002-01-23 | — | — | CN | claimed |
| EP-1127058-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-08-29 | — | — | EP | claimed |
| WO-2000026216-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-05-11 | — | — | WO | claimed |
| US-7223772-B1 | Pyrazolopyridine derivatives as selective cox-2 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| CN-1263755-C | Pyrazolopyridine derivatives as selective COX-2 inhibitors | GLAXO GROUP LTD (GB) | 2006-07-12 | — | — | CN | disclosed |
| EP-1284267-B1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | SANKYO CO (JP) | 2004-12-15 | — | — | EP | disclosed |
| EP-1127058-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LTD (GB) | 2004-09-01 | — | — | EP | disclosed |
| US-6653330-B2 | Such as 4'-chloro-4-(5-(3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4 -triazol-1-y)butyl)-1,3-dioxan-2-yl)-benzanilide; antifungal activity | SANKYO COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | SANKYO COMPANY, LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1284267-A1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | Sankyo Company, Limited (JP) | 2003-02-19 | — | — | EP | disclosed |
| CN-1332741-A | Pyrazolopyridine derivatives as selective COX-2 inhibitors | GLAZO GROUP LTD (GB) | 2002-01-23 | — | — | CN | disclosed |
| EP-1127058-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000026216-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | NAT1, ERG28, DPM1 | MAPK14 1351/4885PTGS2 3052/4885PTGS1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.